SCHEDULE: Intracoastal Capital Discloses 9.99% Stake in Silexion

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a 9.99% passive beneficial ownership in Silexion Therapeutics Corp. ordinary shares.

Summary

• Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (collectively, the "Reporting Persons") have filed a Schedule 13G, indicating beneficial ownership of Silexion Therapeutics Corp. ordinary shares.
• As of September 17, 2025, the Reporting Persons collectively beneficially own 244,771 ordinary shares, representing 9.99% of the class.
• This ownership includes 162,500 ordinary shares issuable upon exercise of Intracoastal Warrant 2 and 82,271 ordinary shares issuable upon exercise of Intracoastal Warrant 3.
• The beneficial ownership percentage is capped at 9.99% due to blocker provisions in the warrants, preventing exercise beyond this threshold.
• Without these blocker provisions, the Reporting Persons' beneficial ownership would have been 357,100 ordinary shares as of September 17, 2025.
• The initial beneficial ownership immediately following the Securities Purchase Agreement (SPA) on September 11, 2025, was deemed to be 81,203 Ordinary Shares, also representing approximately 9.99% due to blocker provisions.

Sentiment

Score: 7

Explanation: The filing indicates a significant, albeit passive, investment by an institutional group, which is generally a positive signal of investor confidence. The blocker provisions, while limiting, ensure compliance with passive investment rules.

Positives

• A significant institutional investor group has taken a substantial 9.99% stake in Silexion Therapeutics Corp., signaling confidence in the company's future.
• The investment was made through a Securities Purchase Agreement, indicating a direct capital infusion into the company.

Negatives

• The presence of blocker provisions in the warrants limits the Reporting Persons' ability to increase their beneficial ownership beyond 9.99%, potentially capping their influence or further investment without triggering a more active filing (Schedule 13D).

Risks

• The filing itself does not detail company-specific risks, but the passive nature of the investment (Schedule 13G) means the Reporting Persons are not seeking to influence or control the issuer, which may limit potential activist-driven value creation.

Future Outlook

The filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Silexion Therapeutics Corp. or the Reporting Persons regarding the company's future performance.

Industry Context

This filing indicates a significant, passive investment by an institutional group in a biotechnology or pharmaceutical company. Such investments are common in the industry, often reflecting a belief in the long-term potential of a company's pipeline or technology, without immediate intent for operational involvement.

Stakeholder Impact

• Shareholders may view the significant investment by Intracoastal Capital and its affiliates as a positive indicator of the company's value and prospects, potentially leading to increased investor interest.
• The capital raised through the Securities Purchase Agreement could provide Silexion Therapeutics Corp. with additional resources for its operations and strategic initiatives.

Key Dates

Recommendation

The disclosure of a significant 9.99% passive stake by an institutional investor group suggests a vote of confidence in Silexion Therapeutics Corp. While this is a positive signal, a Schedule 13G filing alone does not provide sufficient fundamental information to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and monitor future company developments and financial performance, considering this new institutional interest as a supportive factor.

Keywords

Silexion Therapeutics, Schedule 13G, beneficial ownership, Intracoastal Capital, institutional investment, ordinary shares, warrants, passive investment